

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Philippa RADCLIFFE et al.

Title: TRANSGENIC ORGANISM

Appl. No.: 10/082,122

Filing Date: 02/26/2002

Examiner: Unassigned

Art Unit: 1632

RECEIVED

OCT 18

TECH CENTER 1600 2900

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.



Atty. Dkt. No. 078883-0145

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Oct 17, 2002

By Michele M. Simkin

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717

Form PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
078883-0145SERIAL NO.  
10/082,122

APPLICANT

Philippa RADCLIFFE et al.

FILING DATE

02/26/2002

GROUP ART UNIT

1632

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

RECEIVED

OCT 18 2002

TECH CENTER 600-2900

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
9w	A1	GB 2334257	18.08.1999	United Kingdom				
	A2	GB 2228487	29.08.1990	United Kingdom				
	A3	WO 00/66758 A1	09.11.2000	World				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

9w	A4	M.A. Curran et al. "Efficient Transduction of Nondividing Cells by Optimized Feline Immunodeficiency Virus Vectors", <i>Molecular Therapy</i> Vol. 1, No. 1, January 2000, pp. 31-38.						
9w	A5	Julie C. Johnston et al. "Minimum Requirements for Efficient Transduction of Dividing and Nondividing Cells by Feline Immunodeficiency Virus Vectors", <i>Journal of Virology</i> , Vol. 73, No. 6, June 1999, pp. 4991-5000.						

EXAMINER

DATE CONSIDERED

Joe W. Wilbur

10/14/04

- \* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.



Atty. Dkt. No. 078883-0145

#11

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Philippa RADCLIFFE et al.

Title: TRANSGENIC ORGANISM

Appl. No.: 10/082,122

Filing Date: 02/26/2002

Examiner: Unassigned

Art Unit: 1632

RECEIVED  
APR 14 2003  
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.



Atty. Dkt. No. 078883-0145

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

April 11, 2003

By

Michele M. Simkin

FOLEY & LARDNER  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538

Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicants  
Registration No. 34,717

RECEIVED

APR 14 2003

TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: April 11, 2003  (use as many sheets as necessary)				Application Number	10/082.122
				Filing Date	02/26/2002
				First Named Inventor	Philippa RADCLIFFE et al.
				Group Art Unit	1632
Examiner Name				Unassigned	
Attorney Docket Number				078883-0145	
Sheet	1	of	1		

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Office <sup>3</sup> Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
92	A1	WO	03/022228	A2 CALIFORNIA INSTITUTE OF TECHNOLOGY	03/20/2003		
	A2	WO	03/022040	A2 CALIFORNIA INSTITUTE OF TECHNOLOGY	03/20/2003		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
92	A3	LOIS ET AL., "Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors," <i>Science</i> (1 February 2002), Vol. 295, pp. 868-872.	
	A4	QIN ET AL., "Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5," <i>PNAS</i> (January 7, 2003), Vol. 100, No. 1, pp. 183-188.	

RECEIVED  
APR 14 2003  
TECH CENTER 1800-2900

Examiner  
Signature

*Joe W. W. W.*

Date  
Considered

10/14/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Atty. Dkt. No. 078883-0145

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Philippa RADCLIFFE et al.

Title: TRANSGENIC ORGANISM

Appl. No.: 10/082,122

Filing Date: 02/26/2002

Examiner: Unassigned

Art Unit: 1632

**RECEIVED**

JAN 17 2003

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.



Atty. Dkt. No. 078883-0145

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding United Kingdom application. A copy of the United Kingdom Search Report is attached setting forth the portion of each document considered relevant by the examiner.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Jan 16, 2003

By Michele M. Simkin

FOLEY & LARDNER

Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538

Facsimile: (202) 672-5399


Michele M. Simkin

Attorney for Applicants

Registration No. 34,717



Substitute for form 1449B:PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: 01/16/2003  (use as many sheets as necessary)		Application Number	10/082,122
		Filing Date	02/26/2002
		First Named Inventor	Philippa RADCLIFFE et al.
		Group Art Unit	1632
		Examiner Name	Unassigned
Sheet 1 of 1	Attorney Docket Number	078883-0145	



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Office <sup>3</sup> Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T <sup>6</sup>
72	A1	WO	01/44458	A2	NOVARTIS AG	06/21/2001
	A2	WO	00/73482	A1	CHIRON CORP. ET AL.	12/07/2000
	A3	WO	98/51810	A1	UNI. NORTH CAROLINA	11/19/1998

RECEIVED

JAN 17 2003

TECH CENTER 1600 2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. T <sup>6</sup>
72	A4	TARANTAL ET AL., "Lentiviral Vector Gene Transfer into Fetal Rhesus Monkeys ( <i>Macaca mulatta</i> ) <i>Mol. Ther.</i> (2001), Vol. 4, No. 6, pp. 614-621.
	A5	WOLFGANG ET AL., "Rhesus monkey placental transgene expression after lentiviral gene transfer into preimplantation embryos," <i>Proc. Natl. Acad. Sci. USA</i> (2001), Vol. 98, No. 19, pp. 10728-10732.
	A6	STEIN ET AL., "In Vivo Treatment of Hemophilia A and Mucopolysaccharidosis Type VII Using Nonprimate Lentiviral Vectors," <i>Mol. Ther.</i> (2001), Vol. 3, pp. 850-856.
	A7	BERKOWITZ ET AL., "Construction and Molecular Analysis of Gene Transfer Systems Derived from Bovine Immunodeficiency Virus," <i>J. Virol.</i> (2001), Vol. 75, No. 7, pp. 3371-3382.
	A8	TARANTAL ET AL., "Rhesus Monkey Model for Fetal Gene Transfer: Studies with Retroviral-Based Vector Systems," <i>Mol. Ther.</i> (2001), Vol. 3, No. 2, pp. 128-138.

Examiner Signature: <i>Joe Wooten</i>	Date Considered: 10/14/04
---------------------------------------	---------------------------

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant  
<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document  
<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached  
 Burden Hour Statement This form is estimated to take 2.0 hours to complete Time will vary depending upon the needs of the individual case Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO Assistant Commissioner for Patents, Washington, D.C. 20231



2003

1632

PATENT  
674523-2024

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Radcliffe et al.  
U.S. Serial No. : 10/082,122  
Filing Date : February 26, 2002  
For : TRANSGENIC ORGANISM  
Examiner : Unsigned  
Art Unit : 1632

745 Fifth Avenue  
New York, NY 10151

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on September 5, 2003.

Thomas J. Kowalski, Reg. No. 32,147

Name of Applicant, Assignee or Registered Representative

*Thomas J. Kowalski*  
Signature

September 5, 2003

Date of Signature

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Further to the Information Disclosure Statements filed on October 17, 2002, November 25, 2002, January 16, 2003 and April 1 2003, the Examiner's attention is respectfully directed to the accompanying document listed on form PTO-1449.

To the extent that a petition is necessary for consideration of this Information Disclosure Statement, this paper will serve as such. Further, these documents were first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

It is respectfully requested that the Examiner considers and make of record the document cited herewith and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

The filing of this Information Disclosure Statement is not an admission that the document identified herein constitutes prior art to the present application.

As this Information Disclosure Statement is being submitted before receipt of an Office Action, it is believed that no fee is due for the consideration of this document. If, however a fee is due, the Commissioner is authorized to charge any necessary Petition fee, or any additionally required fee, or credit any overpayment, to deposit account 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP  
Attorney for Applicants

By: 

Thomas J. Kowalski  
Reg. No. 32,147  
(212) 588-0800

Encls. - PTO Form 1449  
- 2 References

Based on Form PTO-1449  
(3/90)

ATTY. DOCKET NO.

674523-2024

SERIAL NO.

10/082,122

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Radcliffe, et al.

FILING DATE

February 26, 2002

GROUP

1632

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
9w	AA	6,312,683 B1	11/06/01	Kingsman, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

9w	AQ		Yamada et al. "Functional Correction of Fanconi Anemia Group C Hematopoietic Cells by the Use of a Novel Lentiviral Vector" Molecular Therapy (2001) Vol. 3, No.4, pp 485-490
	AR		
	AS		
	AT		
	AU		
	AV		


EXAMINER

Joe Waiter

DATE CONSIDERED

10/14/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Atty. Dkt. No. 078883-0145

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Philippa RADCLIFFE et al.

Title: TRANSGENIC ORGANISM

Appl. No.: 10/082,122

Filing Date: 02/26/2002

Examiner: Unassigned

Art Unit: 1632

**RECEIVED**

NOV 27 2002

TECH CENTER 1600/2900

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Nov 25, 2002

By Michele M. Simkin

FOLEY & LARDNER  
Customer Number: 22428



22428


PATENT TRADEMARK OFFICE

Telephone: (202) 672-5538  
Facsimile: (202) 672-5399

Michele M. Simkin  
Attorney for Applicant  
Registration No. 34,717

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: November 25, 2002 (use as many sheets as necessary)				Application Number	10/082,122
				Filing Date	02/26/2002
				First Named Inventor	Philippa RADCLIFFE
				Group Art Unit	1632
				Examiner Name	Unassigned
Sheet	1	of	5	Attorney Docket Number	078883-0145



## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
gw	A1	WO	91/10741	A1	CELL GENESYS, INC.	07-25-1991		
	A2	WO	92/17505	A1	BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON	10-15-1992		
	A3	WO	92/21766	A1	BOEHRINGER MANNHEIM GMBH et al.	12-10-1992		
	A4	WO	95/21927	A2	ISIS INNOVATION LIMITED	08-17-1995		
	A5	WO	98/05635	A1	CHIROSCIENCE LIMITED	02-12-1998		
	A6	WO	98/07859	A2	GENETICS INSTITUTE, INC.	02-26-1998		
	A7	WO	98/09985	A2	YEDA RESEARCH AND DEVELOPMENT CO., LTD.	03-12-1998		
	A8	WO	98/15294	A1	THE UNIVERSITY OF SHEFFIELD	04-16-1998		
	A9	WO	98/17815	A1	OXFORD BIOMEDICA LIMITED	04-30-1998		
	A10	WO	99/15683	A1	OXFORD BIOMEDICA LIMITED	04-01-1999		
	A11	WO	99/32646	A1	OXFORD BIOMEDICA LIMITED	07-01-1999		
	A12	WO	99/51755	A2	THE SALK INSTITUTE FOR BIOLOGICAL STUDIES	10-14-1999		
	A13	WO	01/79518	A2	OXFORD BIOMEDICA LIMITED	10-02-2001		

RECEIVED

NOV 27 2002

TECH CENTER 1600/2900

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>
gw	A14	BOWTELL et al., "Comparison of Expression in Hemopoietic Cells by Retroviral Vectors Carrying Two Genes," <i>Journal of Virology</i> , 62(7):2464-2473, American Society for Microbiology, July 1988	

Examiner Signature		Date Considered	10/14/04
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: November 25, 2002  (use as many sheets as necessary)		Application Number	10/082,122
		Filing Date	02/26/2002
		First Named Inventor	Philippa RADCLIFFE
		Group Art Unit	1632
		Examiner Name	Unassigned
Sheet	2	of	5
		Attorney Docket Number	078883-0145



## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
90	A15	BRUCHSCHACHER & PANGANIBAN, "Human Immunodeficiency Virus Vectors for Inducible Expression of Foreign Genes," <u>Journal of Virology</u> , 66(5):2731-2739, American Society of Microbiology, May 1992	/
	A16	BRUICK & McKNIGHT, "A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF," <u>Science</u> , 294:1337-1340, November 9, 2001	/
	A17	CHAN et al., "Transgenic cattle produced by reverse-transcribed gene transfer in oocytes," <u>Proc. Natl. Acad. Sci.</u> , 95:14028-14033, The National Academy of Sciences, November 1998	/
	A18	CHAN et al., "Transgenic Monkeys Produced by Retroviral Gene Transfer into Mature Oocytes," <u>Science</u> , 291:309-312, January 12, 2001	/
	A19	CLABOUGH et al., "Immune-Mediated Thrombocytopenia in Horses Infected with Equine Infectious Anemia Virus," <u>Journal of Virology</u> , 65(11):6242-6251, American Society for Microbiology, November 1991	/
	A20	COFFIN et al., "Retroviruses," pp. 683, 758-763, JM Coffin et al., eds., Cold Spring Harbour Laboratory Press, 1997	/
	A21	CORRELL et al., "Retroviral Vector Design for Long-Term Expression in Murine Hematopoietic Cells in Vivo," <u>Blood</u> , 84(6):1812-1822, The American Society of Hematology, September 15, 1994	/
	A22	CULLEN, "Regulation of HIV gene expression," <u>AIDS</u> , 9 (suppl A):S19-S32, Current Science Ltd., 1995	/
	A23	DERSE & NEWBOLD, "Mutagenesis of EIAV TAT Reveals Structural Features Essential for Transcriptional Activation and TAR Element Recognition," <u>Virology</u> , 194:530-536, Academic Press, Inc., 1993	/
	A24	DOUGHERTY & TEMIN, "A promoterless retroviral vector indicated that there are sequences in U3 required for 3' RNA processing," <u>Proc. Natl. Acad. Sci.</u> , 84:1197-1201, USA, March 1987	/
	A25	EMERMAN & TEMIN, "Genes with Promoters in Retrovirus Vectors Can Be Independently Suppressed by an Epigenetic Mechanism," <u>Cell</u> , 39:459-469, MIT, December 1984 (Part 2)	/
	A26	EPSTEIN et al., "C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxigenases that Regulate HIF by Prolyl Hydroxylation," <u>Cell</u> , 107:43-54, Cell Press, October 5, 2001	/
	A27	GHATTAS et al., "The Encephalomyocarditis Virus Internal Ribosome Entry Site Allows Efficient Coexpression of Two Genes from a Recombinant Provirus in Cultured Cells and in Embryos," <u>Molecular and Cellular Biology</u> , 11(12):5848-5859, American Society for Microbiology, December 1991	/

RECEIVED  
NOV 27 2002  
TECHNICAL CENTER

Examiner  
Signature

*Joe Wottach*

Date  
Considered

10/14/04



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: November 25, 2002

(use as many sheets as necessary)

Sheet


3

of

5

**Complete if Known**

Application Number	10/082,122
Filing Date	02/26/2002
First Named Inventor	Philippa RADCLIFFE
Group Art Unit	1632
Examiner Name	Unassigned
Attorney Docket Number	078883-0145

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
AW	A28	GOODCHILD & KOHLI, "Ribozymes That Cleave an RNA Sequence from Human Immunodeficiency Virus: The Effect of Flanking Sequence on Rate," <u>Archives of Biochemistry and Biophysics</u> , 284(2):386-391, Academic Press, Inc., February 1, 1991	/
	A29	HAASS & KAHLE, "Parkin and Its Substrates," <u>Science</u> , 293:224-225, July 13, 2001	/
	A30	HANTZOPOULOS et al., "Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector," <u>Proc. Natl. Acad. Sci.</u> , 86:3519-3523, May 1989, USA	/
	A31	HATZOGLOU et al., "Hormonal Control of Interacting Promoters Introduced into Cells by Retroviruses," <u>The Journal of Biological Chemistry</u> , 266(13):8416-8425, The American Society for Biochemistry and Molecular Biology, Inc., May 5, 1991, USA	/
	A32	HATZOGLOU et al., "Hormonal Regulation of Chimeric Genes Containing the Phosphoenolpyruvate Carboxykinase Promoter Regulatory Region in Hepatoma Cells Infected by Murine Retroviruses," <u>The Journal of Biological Chemistry</u> , 263(33):17798-17808, The American Society for Biochemistry and Molecular Biology, Inc., November 25, 1988, USA	/
	A33	HAWLEY et al., "Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells," <u>Proc. Natl. Acad. Sci.</u> , 84:2406-2410, USA, April 1987	/
	A34	HERMAN & COFFIN, "Efficient Packaging of Readthrough RNA in ALV: Implications for Oncogene Transduction," <u>Science</u> , 236:845-848, May 15, 1987	/
	A35	JOLLY et al., "Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene," <u>Nucleic Acids Research</u> , 11(6):1855-1872, IRL Press Limited, Oxford, England, 1983	/
	A36	KITADA et al., "Mutations in the <i>parkin</i> gene cause autosomal recessive juvenile parkinsonism," <u>Nature</u> , 392:605-608, April 9, 1998	/
	A37	KRÜGER et al., "Ala30Pro mutation in the gene encoding $\alpha$ -synuclein in Parkinson's disease," <u>Nature Genetics</u> , 18:106-108, February 1998	/
	A38	LEWIS & EMERMAN, "Passage through Mitosis Is Required for Oncoretroviruses but Not for the Human Immunodeficiency Virus," <u>Journal of Virology</u> , 68(1):510-516, American Society for Microbiology, Jan 1994	/
	A39	LEWIS et al., "Human immunodeficiency virus infection of cells arrested in the cell cycle," <u>The EMBO Journal</u> , 11(8):3053-3058, Oxford University Press, 1992	/

TECH CENTER 1600/2900

Examiner  
Signature

Date  
Considered

10/14/04

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

Date Submitted: November 25, 2002

(use as many sheets as necessary)

Sheet

4

of

5

**Complete if Known**

Application Number 10/082,122  
 Filing Date 02/26/2002  
 First Named Inventor Philippa RADCLIFFE  
 Group Art Unit 1632  
 Examiner Name Unassigned  
 Attorney Docket Number 078883-0145

NOV 25 2002

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>a</sup>
90	A40	LI et al., "Comparison of the Expression of a Mutant Dihydrofolate Reductase under Control of Different Internal Promoters in Retroviral Vectors," <u>Human Gene Therapy</u> , 3:381-390, Mary Ann Liebert, Inc., Publishers (1992)	✓
	A41	MARTARANO et al., "Equine infectious Anemia Virus <i>trans</i> -Regulatory Protein Rev Controls Viral mRNA Stability, Accumulation, and Alternative Splicing," <u>Journal of Virology</u> , 68(5):3102-3111, American Society for Microbiology, May 1994	✓
	A42	MAURY et al., "Cellular and Viral Specificity of Equine Infectious Anemia Virus Tat Transactivation," <u>Virology</u> , 200:632-642, Academic Press, Inc., 1994	✓
	A43	McLACHLIN et al., "Factors Affecting Retroviral Vector Function and Structural Integrity," <u>Virology</u> , 195:1-5, Academic Press, Inc. (1993)	✓
	A44	NAGANO et al., "Transgenic mice produced by retroviral transduction of male germ-line stem cells," <u>PNAS</u> , 98(23):13090-13095, November 6, 2001	✓
	A45	NALDINI et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector," <u>Science</u> 272:263-267, April 12, 1996	✓
	A46	OVERELL et al., "Stably Transmitted Triple-Promoter Retroviral Vectors and Their Use in Transformation of Primary Mammalian Cells," <u>Molecular and Cellular Biology</u> , 8(4):1803-1808, American Society for Microbiology, April 1988	✓
	A47	POLYMERPOULOS et al., "Mutation in the $\alpha$ -Synuclein Gene Identified in Families with Parkinson's Disease," <u>Science</u> , 276:2045-2047, June 27, 1997	✓
	A48	ROULEUX et al., "A Negative Regulatory Element of the Macrophage-Specific Human Mannose Receptor Gene Represses Its Expression in Nonmyeloid Cells," <u>Experimental Cell Research</u> , 214:113-119, Academic Press, Inc., 1994	✓
	A49	SCHARFMANN et al., "Long-term <i>in vivo</i> expression of retrovirus-mediated gene transfer in mouse fibroblast implants," <u>Proc. Natl. Acad. Sci.</u> , 88:4626-4630, USA, June 1991	✓
	A50	SHIMURA et al., "Ubiquitination of a New Form of $\alpha$ -Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease," <u>Science</u> , 293:263-269, July 13, 2001	✓
	A51	VILE & RUSSEL, "Retroviruses as vectors," <u>British Medical Bulletin</u> , 51(1):12-30, The British Council (1995)	✓

NOV 27 2002

10- R 1600/2900

Examiner  
Signature

*Joe W. [Signature]*

Date  
Considered

10/14/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT


**Date Submitted: November 25, 2002**

(use as many sheets as necessary)

Sheet	5	of	5
-------	---	----	---


**Complete if Known**

<b>Application Number</b>	10/082,122
<b>Filing Date</b>	02/26/2002
<b>First Named Inventor</b>	Philippa RADCLIFFE
<b>Group Art Unit</b>	1632
<b>Examiner Name</b>	Unassigned
<b>Attorney Docket Number</b>	078883-0145



## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	10/14/04
-----------------------	---	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, D.C. 20231.